--- title: "Moleculin Biotech | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286459134.md" datetime: "2026-05-14T20:03:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286459134.md) - [en](https://longbridge.com/en/news/286459134.md) - [zh-HK](https://longbridge.com/zh-HK/news/286459134.md) --- # Moleculin Biotech | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -3.54. EBIT: As of FY2026 Q1, the actual value is USD -7.908 M. Moleculin Biotech, Inc. operates in a single reportable segment focused on the development and commercialization of drug products, with financial performance reviewed on a consolidated basis primarily using consolidated net loss . #### Operating Expenses - **Research and Development (R&D) Expense**: For the three months ended March 31, 2026, R&D expense increased by $2.0 million to $5.4 million, compared to $3.4 million for the same period in 2025, mainly due to $1.4 million for MIRACLE clinical trials and $0.3 million for nonclinical studies . - **General and Administrative Expense**: This remained stable at $2.5 million for both the three months ended March 31, 2026, and the same period in 2025 . - **Depreciation and Amortization**: This expense decreased to $8,000 for the three months ended March 31, 2026, from $31,000 in the prior year period . - **Total Operating Expenses**: Total operating expenses were $7.9 million for the three months ended March 31, 2026, an increase from $5.9 million for the same period in 2025 . #### Other Income (Loss) - **Gain from Change in Fair Value of Warrant Liability**: Moleculin Biotech, Inc. recorded a net gain of $10.8 million in the first quarter of 2026 . - **Transaction Costs Allocated to Warrant Liabilities**: These costs amounted to - $693,000 in the first quarter of 2026 . - **Loss on Issuance of Warrant Liabilities**: A loss of - $15.2 million was recorded on the issuance of Series H warrants in the first quarter of 2026 . - **Other Income, Net**: This increased to $76,000 for the three months ended March 31, 2026, from $9,000 in the same period of 2025 . - **Interest Income, Net**: This was $34,000 for the three months ended March 31, 2026, up from $30,000 in the prior year period . #### Net Loss - Moleculin Biotech, Inc. reported a net loss of - $12.8 million for the three months ended March 31, 2026, an increase from - $5.9 million for the same period in 2025 . #### Cash Flow - **Net Cash Used in Operating Activities**: Cash used in operations increased by - $1.5 million to - $6.1 million for the three months ended March 31, 2026, compared to - $4.6 million for the prior year, primarily due to the timing of clinical trial expenses and drug production costs . - **Net Cash Provided by Financing Activities**: This was $7.6 million for the three months ended March 31, 2026, slightly down from $8.0 million for the same period in 2025 . - **Effect of Exchange Rate Changes on Cash and Cash Equivalents**: This was - $62,000 for the three months ended March 31, 2026, compared to $3,000 for the same period in 2025 . - **Net Increase in Cash and Cash Equivalents**: This was $1.4 million for the three months ended March 31, 2026, compared to $3.4 million for the same period in 2025 . #### Liquidity and Capital Resources As of March 31, 2026, Moleculin Biotech, Inc. had $10.3 million in cash and cash equivalents, which, combined with $0.8 million raised in May 2026, is expected to fund operations into the third quarter of 2026 . The company requires approximately $25 million in additional funding to support the MIRACLE trial and operations into the first quarter of 2027, which it plans to secure through a combination of equity offerings, debt financings, third-party funding, commercialization arrangements, collaborations, or by delaying planned cash outlays . #### Operational Outlook and Strategy Moleculin Biotech, Inc. is focused on the development of Annamycin, its lead drug candidate, currently in a pivotal Phase 2B/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (R/R AML) . The first unblinding of data from the MIRACLE trial is anticipated before June 30, 2026, with a subsequent unblinding expected in the second half of 2026 to conclude Part A of the trial . As of May 5, 2026, 56 subjects have been recruited, representing 62% of Part A, with a target to recruit the 90th subject in Part A by Q3 2026 . Additionally, the company plans for future Annamycin trials, MB-109 and MB-110, for R/R AML in adults and pediatrics respectively, both scheduled for 2027 . To reduce corporate overhead, Moleculin Biotech, Inc. is closing its Australian subsidiary . ### Related Stocks - [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md) ## Related News & Research - [Moleculin Biotech Q1 net loss widens as R&D costs rise](https://longbridge.com/en/news/286567662.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Bureau Veritas: All resolutions passed at May 19, 2026 Shareholders' Meeting.](https://longbridge.com/en/news/286946080.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Helium Evolution files Q1 2026 financial results.](https://longbridge.com/en/news/286968740.md)